<DOC>
	<DOCNO>NCT00121043</DOCNO>
	<brief_summary>The primary purpose study ass ease-of-use SimpleJectTM compare pre-filled syringe ( ) use Kineret® RA subject . The secondary purpose study ass level fear anxiety associate use injection method , assess safety use SimpleJectTM evaluate Ease-of-Administration Questionnaire ( EAQ ) term quality item , item performance , instrument reliability .</brief_summary>
	<brief_title>Evaluating Kineret® ( Anakinra ) Rheumatoid Arthritis ( RA ) Subjects Using aSelf-Reported Questionnaire</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Subjects must diagnose RA guide ACR criterion Subjects must inadequate response methotrexate alone Subjects must receive concomitant treatment methotrexate study period Before study specific procedure , subject must give informed consent participation study Subject previous experience use SimpleJectTM Prior treatment Kineret® and/or etanercept Less 6 week washout period patient receive prior infliximab treatment Subject currently enrol clinical trial , receive investigational agent ( ) , least 30 day period elapse since completion investigational trial device ( ) drug ( ) Subject currently infection require systemic antiinfective therapy Baseline neutropenia ( le 1.5 x 10^9/l ) Subjects severe renal impairment ( CLCR le 30 ml/minute ) Subjects willing use adequate birth control method Women childbearing potential pregnant , breastfeed plan become pregnant study Planned administration live vaccine study period Subject available followup assessment Subjects known sensitivity Kineret® excipients E. coli derive protein Preexisting malignancy Any condition investigator opinion would preclude subject participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Rheumatoid Arthritis , Inflammation</keyword>
	<keyword>Interleukin-1 ( IL-1 ) , r-metHuIL-1ra</keyword>
	<keyword>Autoimmune , Kineret®</keyword>
	<keyword>Anakinra , Immunex</keyword>
	<keyword>Amgen , Clinical Trials</keyword>
</DOC>